AU2004275696B2 - Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation - Google Patents

Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation Download PDF

Info

Publication number
AU2004275696B2
AU2004275696B2 AU2004275696A AU2004275696A AU2004275696B2 AU 2004275696 B2 AU2004275696 B2 AU 2004275696B2 AU 2004275696 A AU2004275696 A AU 2004275696A AU 2004275696 A AU2004275696 A AU 2004275696A AU 2004275696 B2 AU2004275696 B2 AU 2004275696B2
Authority
AU
Australia
Prior art keywords
gmp
biofilm
microbial
aureus
colonization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004275696A
Other languages
English (en)
Other versions
AU2004275696A1 (en
Inventor
David K. R. Karaolis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KARAGEN PHARMACEUTICALS Inc
Original Assignee
Karagen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karagen Pharmaceuticals Inc filed Critical Karagen Pharmaceuticals Inc
Publication of AU2004275696A1 publication Critical patent/AU2004275696A1/en
Application granted granted Critical
Publication of AU2004275696B2 publication Critical patent/AU2004275696B2/en
Assigned to KARAGEN PHARMACEUTICALS, INC. reassignment KARAGEN PHARMACEUTICALS, INC. Request for Assignment Assignors: KARAOLIS, DAVID
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AU2004275696A 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation Ceased AU2004275696B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49002903P 2003-07-28 2003-07-28
US60/490,029 2003-07-28
PCT/US2004/023498 WO2005030186A2 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation

Publications (2)

Publication Number Publication Date
AU2004275696A1 AU2004275696A1 (en) 2005-04-07
AU2004275696B2 true AU2004275696B2 (en) 2010-02-18

Family

ID=34392905

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004275696A Ceased AU2004275696B2 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation

Country Status (7)

Country Link
US (1) US8367716B2 (enExample)
EP (1) EP1651242A2 (enExample)
JP (1) JP2007500697A (enExample)
AU (1) AU2004275696B2 (enExample)
CA (1) CA2533873A1 (enExample)
IL (1) IL173065A (enExample)
WO (1) WO2005030186A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1740192B1 (en) 2004-03-15 2012-06-13 David K. R. Karaolis Cyclic dinucleotide for stimulating the immune of inflammatory response
WO2006073514A2 (en) * 2004-08-25 2006-07-13 Tufts University Compositions, methods and kits for repressing virulence in gram positive bacteria
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
EP2254591B1 (en) 2008-02-08 2017-07-26 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms
WO2009133560A1 (en) * 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
EP2448954A1 (en) * 2009-07-01 2012-05-09 Rutgers, The State University of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
CN102199183B (zh) * 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
CN101843899B (zh) * 2010-05-24 2012-11-07 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌（mrsa）重组多亚单位基因工程疫苗及其制备方法
WO2012021554A1 (en) * 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
WO2013185052A1 (en) 2012-06-08 2013-12-12 Aduro Biotech Compostions and methods for cancer immunotherapy
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
MX365661B (es) 2012-12-19 2019-06-10 Univ Texas Activacion farmaceutica de una senda de señalizacion de di-nucleotido ciclico de mamifero.
CN104152472A (zh) * 2012-12-28 2014-11-19 陶飞 一种双鸟苷酸环化酶基因、载体、工程菌及其应用
JP6153116B2 (ja) * 2013-01-09 2017-06-28 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
CA2908154C (en) 2013-04-29 2023-11-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
JP6400082B2 (ja) * 2013-05-18 2018-10-03 アデュロ バイオテック，インコーポレイテッド 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
ES2692226T3 (es) 2014-06-04 2018-11-30 Glaxosmithkline Intellectual Property Development Limited Dinucleótidos cíclicos como moduladores de STING
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
MX363780B (es) 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
CN114751950B (zh) 2016-03-18 2025-04-18 免疫传感器公司 环二核苷酸化合物及使用方法
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
PE20210156A1 (es) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020031083A1 (en) * 2018-08-06 2020-02-13 KHAN, Khalid Antimicrobial formulations comprising vancomycin or tobramycin
WO2020227421A1 (en) 2019-05-09 2020-11-12 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
CN114085887A (zh) * 2020-08-25 2022-02-25 中国科学院大连化学物理研究所 一种基于仿生微球的铜绿假单胞菌耐药浓度的检测方法
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
CN114099657B (zh) * 2021-11-04 2022-05-17 暨南大学 一种溶藻弧菌减毒活疫苗及其制备方法与应用
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
CN118956719B (zh) * 2024-07-31 2025-05-09 武汉市仪泰环境科技有限公司 一种毒性检测中加快微生物挂膜的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268274A (en) * 1989-04-12 1993-12-07 Cetus Corporation Methods and nucleic acid sequences for the expression of the cellulose synthase operon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1672492A (en) * 1991-05-03 1992-12-21 University Technologies International Inc. Biofilm reduction method
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US20020091074A1 (en) * 2000-09-20 2002-07-11 Wooley Richard E. Medical compositions, dressings and methods for treating microbial infections of skin lesions
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
JP2002302404A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 抗菌防黴助剤
US7189351B2 (en) * 2001-10-25 2007-03-13 Spherix Incorporated D-tagatose as an anti-biofilm agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268274A (en) * 1989-04-12 1993-12-07 Cetus Corporation Methods and nucleic acid sequences for the expression of the cellulose synthase operon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ross et al, "Regulation of cellulose synthesis in Acetobacter xylinum by cyclic diguanylic acid" Nature 1987, 325:279-81 *

Also Published As

Publication number Publication date
WO2005030186A2 (en) 2005-04-07
US8367716B2 (en) 2013-02-05
AU2004275696A1 (en) 2005-04-07
IL173065A (en) 2011-05-31
JP2007500697A (ja) 2007-01-18
WO2005030186A3 (en) 2005-07-14
EP1651242A2 (en) 2006-05-03
CA2533873A1 (en) 2005-04-07
US20070244059A1 (en) 2007-10-18
IL173065A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
AU2004275696B2 (en) Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
Langendonk et al. The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-breaking therapies
Gaca et al. Adaptation to adversity: the intermingling of stress tolerance and pathogenesis in enterococci
Fernández et al. Creeping baselines and adaptive resistance to antibiotics
Van Laar et al. Sublethal concentrations of carbapenems alter cell morphology and genomic expression of Klebsiella pneumoniae biofilms
Arias et al. The rise of the Enterococcus: beyond vancomycin resistance
Mitchell et al. Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to Pseudomonas aeruginosa 4-hydroxy-2-heptylquinoline-N-oxide
Espinel et al. Multiple roles of putrescine and spermidine in stress resistance and virulence of Salmonella enterica serovar Typhimurium
Duménil Type IV pili as a therapeutic target
Martinez Mechanisms of action and of resistance to quinolones
Lahiri et al. Biofilm and antimicrobial resistance
Mechesso et al. Tylosin exposure reduces the susceptibility of Salmonella Typhimurium to florfenicol and tetracycline
Hemlata et al. The ever changing face of antibiotic resistance: Prevailing problems and preventive measures
Alam et al. Biofilms: A phenotypic mechanism of bacteria conferring tolerance against stress and antibiotics
Astrauskiene et al. New insights into bacterial persistence in reactive arthritis
Jolivet‐Gougeon et al. Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved
Wagley et al. A proteasome inhibitor produced by Burkholderia pseudomallei modulates intracellular growth
Ravishankar Investigation of antibiofilm and antivirulence activity of 5-fluorocytosine in Escherichia coli
Gómez et al. Transcriptomic analysis of sub-MIC Eugenol exposition on antibiotic resistance profile in Multidrug Resistant Enterococcus faecalis E9. 8
Kanwar et al. Oral Microbiome and Drug Resistance
Thapa From Regulation of Secondary Metabolites to Increased Virulence Under Sublethal Dosage of Antibiotics: An Unprecedented Role of Global Regulator, MftR, in Burkholderia Thailandensis
Krath Investigation of a cryptic aminoglycoside resistance gene in Salmonella Enterica subspecies Enterica Serovar typhimurium
Rothstein et al. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae
Elkrewi Investigating the prevalence and genetic basis of resistance to the antimicrobial agents bacitracin, nitrofurantoin and silver in key pathogenic bacteria
Scoffone et al. Antimicrobial drug efflux pumps in Burkholderia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 22 JUL 2012 TO 22 FEB 2013 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 22 FEB 2013 .

PC Assignment registered

Owner name: KARAGEN PHARMACEUTICALS, INC.

Free format text: FORMER OWNER WAS: KARAOLIS, DAVID

MK14 Patent ceased section 143(a) (annual fees not paid) or expired